Biogen shares rise as drugmaker avoids ‘worst case scenario’ in patent dispute

One of Massachusetts’ biggest drugmakers may have two more contests coming down the pipeline over its best-selling drug, but at least one analyst believes the company avoided the “worst case scenario” this week.